The Annual International PfSPZ Consortium Met in Toronto, Canada

The Annual International PfSPZ Consortium Met in Toronto, Canada on November 8th & 9th, 2025

December 10, 2025 By In News No Comments
The 2025 iPfSPZ-C meeting brought together scientists from around the world to review an extraordinary year of progress in Plasmodium falciparum sporozoite (PfSPZ) vaccine and other SPZ research. Over a day and a half, 48 scientists from 11 countries presented major scientific breakthroughs, steady advances in product development, and coordinated plans for global evaluation of Sanaria’s PfSPZ-based malaria vaccines to the in-person participants and on-line participants around the world.
Read More

SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES

June 30, 2021 By In Press Releases No Comments
In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
Read More

Optimizing immunization with Sanaria® PfSPZ-CVac malaria vaccine

June 8, 2021 By In Press Releases No Comments
Sanaria and its collaborators have had to take a step by step empirical approach to optimizing immunization with PfSPZ vaccines to achieve a safe, effective, durable, and broadly protective malaria vaccine. Two recent landmark malaria vaccine studies have moved the optimization process forward and highlighted the strong protective efficacy of Sanaria® PfSPZ-CVac in malaria-naïve adults.
Read More

Sanaria and Protein Potential Host Shari Davis Who Facilitated a Discussion: Let’s Talk About Race & Racism

June 16, 2020 By In Uncategorized No Comments
In an effort to support the end of, and continue the discussion about systemic racism, Sanaria Inc. and Protein Potential, LLC hosted Ms. Shari Davis, ACC, SPHR, SHRM-SCP, President and CEO of Venture HCM LLC. Ms. Davis gave a presentation to and facilitated a discussion with our staff about the Black Lives Matter movement.
Read More

Sanaria and its Bioko Island Malaria Elimination Project partners win the Concordia P3 Impact Award and Audience Choice Award

September 24, 2019 By In Awards, In The Media, News No Comments
The Bioko Island Malaria Elimination Project (BIMEP) is a long-term partnership dedicated since 2004 to the elimination of malaria from Equatorial Guinea which had one of the highest rates of malaria transmission and where the disease was the leading cause of morbidity and mortality.
Read More

News Categories

About Sanaria

Sanaria is a Maryland-based biotechnology company developing innovative vaccines that protect against malaria. We are focused on African children, the population most urgently in need of protection.

Latest News

Behind the Scenes: Vaccine Manufacturing

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: